English to Chinese: Medical Patents
General field: Medical
Detailed field: Patents | |
Source text - English
FIELD OF THE INVENTION
The present invention relates to the application of Neuregulin in the preparation of medications for preventing, treating or delaying human heart failure and the methods for the administration of the said medications therefor.
In particular, the present invention provides a method for preventing, treating or delaying human heart failure by administering Neuregulin-based medications to a specific population of patients with heart failure.
The said method involves pre-treatment testing and determination of appropriate treatment for a patient based on the test results.
BACKGROUND OF THE INVENTION
A promising new treatment involves the administration of neuregulin (NRG), a glucoprotein with a molecular weight of 440KD, to patients with HF or at risk of HF; NRGs are proteins involved in intercellular signaling, which act as ligands bound to the ErbB family of receptor tyrosine kinases.
| Translation - Chinese
发明领域
本发明涉及在制备用于预防、治疗或延缓人类心力衰竭的药物中应用神经调节素，以及上述药物的给药方法。
特别是，本发明提供了一种通过向特定心力衰竭患者群体施用基于神经调节素的药物来预防、治疗或延缓人类心力衰竭的方法。
该方法包括预治疗测试和根据测试结果为患者确定适当的治疗方案。
发明背景
一个有前景的新治疗方法涉及向心力衰竭患者或有心力衰竭风险的患者施用神经调节素（NRG），这是一种分子量为440KD的糖蛋白。
神经调节素是参与细胞间信号传递的蛋白质，它们作为配体与ErbB家族的受体酪氨酸激酶结合。 |
English to Chinese: Medical CMC
General field: Medical
Detailed field: Medical (general) | |
Source text - English
Dry Mixing & Wet Granulation:
Load the Dabigatran Etexilate Mesylate and sifted material from Step No. 22 and 23 into Saizoner Mixer granulator, mix for 05 minutes by setting at Impeller at slow speed (100 RPM) and chopper at off condition. After completion of mixing rack the dry blend to remove powder sticking to the side of the Saizoner mixer granulator bowl.
Add binder solution from step No.26 to the step no. 27 over a period of 2 minutes by setting impeller at slow speed (100 RPM) and chopper at off condition.
Add the remaining quantity of isopropyl Alcohol to the step no. 28 over a period of 01 minute by setting Impeller at slow Speed (100 RPM) and Chopper at off condition. Unloading the wet granules.
Sifting and Milling:
Sift the dried granules through ASTM # 30 sieve and collect the oversized and passed granules in double polythene bag.
Mill the oversized granules from the above step no. 32 by using 1016μ (40G) screen.
Sift the milled granules through ASTM # 30 sieve and collect the oversized and passed granules in double polythene bag.
Mill the retained granules from the step no. 34 by using 813μ (32R) screen. Ensure total granules should pass through ASTM # 30 sieves.
| Translation - Chinese
干混和湿造粒：
先将达比加群酯甲磺酸盐和第22、23步筛选后的物料加入赛松尔混合造粒机。设定搅拌器速度为慢速（100转/分钟），剁碎机关闭，进行5分钟的混合。混合完毕后，清理干燥混合物，移除粘附在赛松尔混合器造粒机碗壁的粉末。接着，逐渐在2分钟内添加第26步的粘合剂溶液至第27步，同时保持搅拌器慢速运转并关闭剁碎机。然后，在1分钟内将剩余的异丙醇加入至第28步，仍保持搅拌器慢速和剁碎机关闭。最后，将湿颗粒卸出。
筛选和磨碎：
将干燥的颗粒通过ASTM #30筛子进行筛选，收集过筛和过大的颗粒于双层聚乙烯袋中。然后，使用1016微米（40G）筛网将第32步中过大的颗粒进行磨碎。继续使用ASTM #30筛子对磨碎的颗粒进行筛选，并同样收集过筛和过大的颗粒。之后，使用813微米（32R）筛网对第34步中保留的颗粒进行磨碎，确保所有颗粒都能通过ASTM #30筛子。
|
English to Chinese: Medical Equipment
General field: Medical
Detailed field: Medical (general) | |
Source text - English
Programming and Running samples
1.Put the kit into any empty position of the reagent chamber of the BioCLIA instruments. Details of the kit can be uploaded into the instrument system through the scanning of reagent barcode, and can also be set manually.
2.The information of calibrator / quality control is identified by scanning the calibrator / control barcodes, and the position of calibrator / quality control is assigned in the instrument system.
3.The sample to be tested is placed on the instrument sample rack chamber, and the corresponding test information is edited through the instrument supporting software.
4.Start the operation procedure, and all calibrator / quality control / sample processing steps will be automatically executed.
PERFORMANCE CHARACTERISTICS
ACCURACY / SPIKED RECOVERY
The accuracy/spiked recovery was determined by analyzing samples spiked with known amounts of antibody into sample matrix. Specific antibody positive samples (low 100 RU/mL, mid 200 RU/mL, high 300RU/mL) were spiked into two matrixes (50 and 100 RU/ml) separately at the volume ratio of 1.9, making totally 6spiked samples and each sample was tested in triplicate. The spiked recovery for the concentration of autoantibodies to specific antigen was calculated.*
| Translation - Chinese
程序和运行样本
1.将试剂盒放入BioCLIA仪器的试剂室的任一空位中。试剂盒的详细信息可以通过扫描试剂条形码上传到仪器系统中，也可以手动设置。
2.通过扫描校准器/质控的条形码来识别校准器/质控的信息，并在仪器系统中指定校准器/质控的位置。
3.将待测样本放置在仪器的样本架室内，并通过仪器支持的软件编辑相应的测试信息。
4.启动操作程序，所有的校准器/质控/样本处理步骤将自动执行。
性能特性
准确性/添加回收率
通过分析加入已知抗体量的样本矩阵来确定准确性/添加回收率。具体的抗体阳性样本（低浓度100 RU/mL、中浓度200 RU/mL、高浓度300 RU/mL）分别加入两种不同浓度的矩阵（50和100 RU/mL）中，按体积比1.9进行操作，共制备了6种添加样本，每个样本进行三次重复测试。计算了特定抗原的自身抗体浓度的添加回收率。
|
Chinese to English: Medical Clinical Trial
General field: Medical
Detailed field: Medical (general) | |
Source text - Chinese
在本试验给药方式和给药剂量范围内，西奥罗尼胶囊（Chiauranib Capsules）在晚期实体瘤患者中耐受性较好，不良反应多为轻至中度。常见的不良反应为乏力、蛋白尿、血尿、甲状腺功能减退症、高甘油三脂血症、高血压、结合胆红素升高、嗜中性粒细胞减少、恶心、腹泻、淀粉酶增加等。
西奥罗尼胶囊剂量限制性毒性为3级高血压，DLT 剂量为 65mg，MTD为50mg。
本研究未观察到CR、PR的病例，最佳疗效评价为SD的患者12例（66.7%），PD 6例（33.3%），SD > 8 周者为 6 例（33.3%），临床获益率为33.3%。中位 TTP 为 89 天。
西奥罗尼胶囊在肿瘤患者体内的PK行为呈现典型的一级线性药代动力学特征，患者在多个治疗周期后的稳态血药谷浓度与第一周期基本一致，体内血药暴露维持在一个稳定的水平，临床DLT剂量（65 mg）下的稳态药物吸收仍未达到饱和。
患者服用西奥罗尼胶囊后，血浆VEGF含量上升与血浆sVEGFR2含量下降的幅度与服药剂量相关，但未观察到患者临床获益与PD指标的相关性。
后续临床试验推荐剂量为50mg，每天服药一次，连续服药。
| Translation - English
Within the administration method and dosage range of this trial, Chiauranib Capsules demonstrated good tolerance in patients with advanced solid tumors, with most adverse reactions being mild to moderate. Common adverse reactions include fatigue, proteinuria, hematuria, hypothyroidism, hypertriglyceridemia, hypertension, elevated conjugated bilirubin, neutropenia, nausea, diarrhea, and increased amylase, among others.
The dose-limiting toxicity (DLT) of Chiauranib Capsules was Grade 3 hypertension, with a DLT dose of 65mg and a maximum tolerated dose (MTD) of 50mg.
In this study, no cases of Complete Response (CR) or Partial Response (PR) were observed. The best therapeutic effect was Stable Disease (SD) in 12 patients (66.7%), with Progressive Disease (PD) in 6 patients (33.3%). Six patients (33.3%) had SD for more than 8 weeks, and the clinical benefit rate was 33.3%. The median Time to Progression (TTP) was 89 days.
The pharmacokinetic (PK) behavior of Chiauranib Capsules in cancer patients exhibited typical first-order linear pharmacokinetics. After multiple treatment cycles, the steady-state trough concentration of the drug in patients was consistent with that of the first cycle, maintaining a stable level of drug exposure in the body. Under the clinical DLT dose (65 mg), steady-state drug absorption had not yet reached saturation.
After patients took Chiauranib Capsules, the increase in plasma VEGF levels and the decrease in plasma sVEGFR2 levels were dose-related. However, no correlation between clinical benefits and PD markers was observed.
The recommended dose for subsequent clinical trials is 50mg, taken once daily, continuously.
|
Chinese to English: Medical Patents
General field: Medical
Detailed field: Patents | |
Source text - Chinese
技术背景
成纤维细胞生长因子受体(FGFR) 是和成纤维细胞生长因子配体相结合的酪氨酸激酶受体。目前已经有4种FGFR受体被发现能够结合配体，并在包括组织分化，血管生成，伤口愈合，和代谢调节的多种生理性的过程中密切相关。当配体结合时，受体会发生二聚化和磷酸化，刺激蛋白激酶活性活化，并招募许多细胞内蛋白相结合。这些蛋白相互作用能帮助一系列胞内信号传导通路的活化，包括Ras-MAPK, AKT-PI3K, 以及磷酸酯酶C这些对细胞生长，增殖以及生存非常重要的信号通路。
该信号通路的异常激活，比如FGF配体的过表达或者通过FGFR的活化突变会带来肿瘤生长，进展以及对于传统癌症疗法的抗性。在人类肿瘤中，能带来不依赖于配体的受体激活的基因上的变化，包括基因扩增，染色体转位以及体突变等等已经有被描述。而大批量对于上千肿瘤样品的DNA测序已经揭示FGFR信号通路中的组成成分是人类癌症中高频率突变的基因。比如FGFR1的体细胞突变已经在神经胶质瘤和肺癌中被发现，FGFR2的突变多见于胃癌和子宫内膜 | Translation - English
Technical Background
Fibroblast Growth Factor Receptors (FGFRs) are tyrosine kinase receptors that bind to fibroblast growth factor ligands. Four types of FGFR receptors have been discovered, which bind to ligands and are closely related to various physiological processes including tissue differentiation, angiogenesis, wound healing, and metabolic regulation. When the ligand binds, the receptor dimerizes and phosphorylates, stimulating the activation of protein kinase activity and recruiting numerous intracellular proteins to bind. These protein interactions help activate a series of intracellular signaling pathways, including critical pathways for cell growth, proliferation, and survival, such as Ras-MAPK, AKT-PI3K, and phospholipase C.
Abnormal activation of this signaling pathway, such as overexpression of FGF ligands or activating mutations through FGFR, can lead to tumor growth, progression, and resistance to traditional cancer therapies. In human tumors, genetic changes that lead to receptor activation independent of the ligand, including gene amplification, chromosomal translocation, and somatic mutations, have been described. Large-scale DNA sequencing of thousands of tumor samples has revealed that components of the FGFR signaling pathway are frequently mutated genes in human cancers. For example, somatic mutations in FGFR1 have been found in gliomas and lung cancer, FGFR2 mutations are common in stomach cancer and endometrial cancer, FGFR3 mutations in bladder cancer and multiple myeloma, and FGFG4 mutations in primary rhabdomyosarcoma.
|
English to Chinese: IT Software
General field: Tech/Engineering
Detailed field: Computers: Software | |
Source text - English
1） Details of each component are as follows:
Order Simulator: This component is responsible for generating the orders. The orders can be picked up either from a specified order file or can be generated on-the-fly. The latter mechanism is currently being developed so that it writes to an order file. It assumes that specified security ids, user ids, price and quantity ranges, and order to trade ratios are specified. Likewise, it assumes that percentage of orders per security and per user are specified. Based on the specifications it will generate an order with the security and user ids randomly generated as per the distribution specified. The price and quantity generated will be random within the range specified. If this option is not chosen, then an input order file will have to be provided where each order line will contain information about the tuple at the minimum. Currently, only limit orders are supported. Order injection rate is controlled separately by the injector component.
2）IT company profile
LANDesk delivers cost-effective and intelligent systems, security and process management solutions. LANDesk® solutions simplify IT management of desktops, servers, mobile devices and processes. LANDesk has focused on developing systems and security management solutions for more than 19 years and is now leading the convergence of the systems and security and business process management markets. With solid partner relationships and solutions successfully deployed on tens of millions of nodes at leading enterprises worldwide
| Translation - Chinese
1）各个组件的详细信息如下所示:
订单模拟器：该组件负责生成订单。订单可以从指定的订单文件中提取，也可以即时生成。目前正在开发的后一种机制会将生成的订单写入订单文件。它假定指定了安全性ID、用户ID、价格和数量范围，以及订单到交易的比率。同样，假定了每种安全性和每个用户的订单百分比。基于这些规格，它将生成一个订单，订单中的安全性和用户ID将根据指定的分布随机生成。生成的价格和数量将在指定范围内随机。如果不选择此选项，则必须提供一个输入订单文件，其中每个订单行将至少包含等信息。目前，仅支持限价订单。订单注入率由注入器组件单独控制。
2）IT公司概况
LANDesk 提供成本效益高且智能的系统、安全和流程管理解决方案。LANDesk®的解决方案简化了桌面、服务器、移动设备和流程的IT管理。LANDesk 致力于开发系统和安全管理解决方案已有超过19年的历史，并且现在正在引领系统与安全以及业务流程管理市场的融合。LANDesk 与合作伙伴关系稳固，并且其解决方案已在全球领先企业的数千万节点上成功部署。
|
English to Chinese: Business Accounting
General field: Bus/Financial
Detailed field: Accounting | |
Source text - English
Assets
AS1000 Cash – Enter the balance at the end of the period that equals the sum of all balances in bank accounts, petty cash and clearing accounts (e.g. deposits in transit). Reclassify non-interest bearing overdrafts of all deposit and disbursement cash accounts participating in a "Centralized Cash Management System" to LB2200 Accounts Payable – Centralized Cash Management. Reclassify interest bearing overdrafts of all cash accounts to LB1200 Notes and Loans Payable-Bank Overdraft.
AS1100 Cash Equivalents – Enter the balance at the end of the period equal to all Short-Term investments that mature in 90 days or less from the date of purchase by the PepsiCo reporting entity.
AS1150 Other Short-Term Investments – Enter the balance at the end of the period equal to all Short-Term Investments that have original maturities of 91 days or more but less than one year. This amount is the total cost less any valuation reserve and reserve for amortization of premiums. The balance should agree to the total Other Short-Term Investments Balance at End of Quarter reported on Schedule Q-07 – Other Short-Term Investments.
Short-Term Investments that have original maturities in excess of one year, or are intended to be held for more than one year, or lack an organized and active market should be included in Other Investments, AS6300 of this schedule.
| Translation - Chinese
资产
AS1000 现金：
在期末，请录入所有银行账户、小额现金和清算账户（例如在途存款）的余额总和。将所有参与“集中现金管理系统”的存款和支付现金账户的非利息透支重新分类到LB2200 应付账款－集中现金管理。将所有现金账户的计息透支重新分类到LB1200 票据及贷款应付-银行透支。
AS1100 现金等价物：
在期末，请录入等于所有短期投资的余额，这些短期投资自购买之日起90天或更短时间内到期，为百事公司报告实体所持有。
AS1150 其他短期投资：
在期末，请录入等于所有短期投资的余额，这些短期投资的原始到期期限为91天或更多但少于一年。此金额是总成本减去任何估值准备和溢价摊销准备的金额。余额应与“季度末其他短期投资余额”报表Q-07上报告的总额相符。
原始到期期限超过一年的、打算持有超过一年的、或缺乏有组织且活跃市场的短期投资应归入其他投资，即AS6300类别。
|
Chinese to English: 5G Electronic Communication Patents
General field: Tech/Engineering
Detailed field: Patents | |
Source text - Chinese
权利
1. 一个配置为执行操作的网络的位置管理功能（LMF）包括： 接收一个有效时序误差的指示，用于下行链路到达时间差（DL-TDOA）定 位技术，其中该有效时序误差与一组配置用于传输 DL-TDOA 定位参考信号的 基站相关联； 并向执行与 DL-TDOA 相关操作的用户设备（UE）提供该有效时序误差。
2. 权利要求 1 中的 LMF，其中提供有效时序误差包括传输一个 LTE 位置协议 （LPP）提供辅助数据消息，该消息包含有效时序误差。
3. 权利要求 2 中的 LMF，其中 LPP 提供辅助数据消息还包括对一组基站中某 一个基站的指示以及与有效时序误差相关的该基站的面板识别信息。
4. 权利要求 1 中的 LMF，其中提供有效时序误差包括指示一组基站中的某个 基站广播包含有效时序误差的系统信息块（SIB）。
5. 权利要求 4 中的 LMF，其中 SIB 还包括对一组基站中某一个基站的指示以 及与有效时序误差相关的该基站的面板识别信息。
6. 权利要求 1 中的 LMF，其中有效时序误差包括一个时间戳，指示有效时序 误差何时有效或应当应用的时间。
7. 权利要求 1 中的 LMF，其中有效时序误差包括一个绝对值或一个累积值， 用于加到之前提供的有效时序误差值上。
8. 权利要求 1 中的 LMF，其中操作还包括： 接收来自用户设备（UE）的 LPP 提供位置信息消息，该消息包含 UE 的位 置指示，其中 UE 根据下行链路到达时间差（DL-TDOA）计算了位置，并且 LPP 提供位置信息消息还包括至少基于有效时序误差计算位置的指示 规格说明
[0001] 这些示例性实施例可以与多种不同类型的定位技术一起使用。 定 位技术的例子包括下行链路（DL）到达时间差（DL-TDOA）技术、上行链路 （UL）到达时间差（UL-TDOA）技术、上行链路到达角（UL-AOA）技术、下 行链路发射角（DL-AOD）技术以及多次往返时间（multi-RTT）技术 精通 此领域的专业人士会理解，这些定位技术仅为示例性的，而且这些示例性实施 例也可以与其他类型的定位技术一起使用。
[0002] 此外，在整个描述中，可以考虑每种定位技术分为两类。 第一类 是基于用户设备（UE）的定位技术。 基于用户设备（UE）的定位技术通常包 括由用户设备执行定位计算。 第二类是用户设备辅助的定位技术。 用户设 备辅助的定位技术通常包括网络组件或功能（例如，LMF）根据用户设备提供 的至少部分信息执行定位计算。 应该理解，这些示例性实施例可以应用于基 于用户设备的或用户设备辅助的定位技术。 下文描述将识别在不同类别的定 位技术中实施这些示例性实施例时的任何差异。
| Translation - English
Claims
1. A location management function (LMF) of a network configured to perform operations comprising: receiving an indication of an effective timing error for a downlink time difference of arrival (DL-TDOA) positioning technique, wherein the effective timing error is associated with a set of base stations configured to transmit positioning reference signals for the DL-TDOA; and providing the effective timing error to a user equipment (UE) performing operations related to the DL TDOA.
2. The LMF of claim 1, wherein the providing the effective timing error comprises transmitting an LTE Position Protocol (LPP) Provide Assistance Data message including the effective timing error.
3. The LMF of claim 2, wherein the LPP Provide Assistance Data message further comprises an indication of one of the set of base stations and a panel identification of the one of the set of base stations associated with the effective timing error.
4. The LMF of claim 1, wherein the providing the effective timing error comprises instructing one of the set of base stations to broadcast a system information block (SIB) including the effective timing error.
5. The LMF of claim 4, wherein the SIB further comprises an indication of one of the set of base stations and a panel identification of the one of the set of base stations associated with the effective timing error.
6. The LMF of claim 1, wherein the effective timing error comprises a time stamp indicating one of when the effective timing error is valid or when the effective timing error should be applied.
7. The LMF of claim 1, wherein the effective timing error comprises one of an absolute value or an accumulated value to be added to a previous provided effective timing error value.
8. The LMF of claim 1, wherein the operations further comprise: receiving, from the UE, a LPP Provide Location Information message comprising an indication of a position of the UE, wherein the UE has calculated the position based on the DL-TDOA, and wherein the LPP Provide Location Information message further comprises an indication of whether the position has been calculated based on at least the effective timing error.
Specification
[0001] The exemplary embodiments may be used with multiple different types of position techniques. Examples of positioning techniques include a downlink (DL) Time Difference of Arrival (DL-TDOA) technique, an uplink (UL) TDOA (UL-TDOA) technique, a UL Angle of Arrival (UL-AOA) technique, a DL Angle of Departure (DL-AOD) technique and a multi-Round Trip Time (multi-RTT) technique. Those skilled in the art will understand that these positioning techniques are only exemplary, and the exemplary embodiments may be used with other types of positioning techniques.
[0002] In addition, throughout this description, it may be considered that there are two categories of each positioning technique. The first category is UE-based positioning techniques. UE-based positioning techniques generally include the UE performing the positioning calculations. The second category is UE-assisted positioning techniques. UE-assisted positioning techniques generally include a network component or function (e.g., LMF) performing the positioning calculations based on at least some information provided by the UE. It should be understood that the exemplary embodiments may be applied to either UE-based or UE assisted positioning techniques. The below description will identify any differences in implementing the exemplary embodiments in the different categories of positioning techniques.
|
Portfolio